Gene expression in thiazide diuretic or statin users in relation to incident type 2 diabetes

Suchy-Dicey, Astrid; Heckbert, Susan R.; Smith, Nicholas L.; McKnight, Barbara; Rotter, Jerome I.; Chen, Y. D. Ida; Psaty, Bruce M.; Enquobahrie, Daniel A.
January 2014
International Journal of Molecular Epidemiology & Genetics;2014, Vol. 5 Issue 1, p22
Academic Journal
Thiazide diuretics and statins are used to improve cardiovascular outcomes, but may also cause type 2 diabetes (T2DM), although mechanisms are unknown. Gene expression studies may facilitate understanding of these associations. Participants from ongoing population-based studies were sampled for these longitudinal studies of peripheral blood microarray gene expression, and followed to incident diabetes. All sampled subjects were statin or thiazide users. Those who developed diabetes during follow-up comprised cases (44 thiazide users; 19 statin users), and were matched to drug-using controls who did not develop diabetes on several factors. Supervised normalization, surrogate variable analyses removed technical bias and confounding. Differentially-expressed genes were those with a false discovery rate Q-value<0.05. Among thiazide users, diabetes cases had significantly different expression of CCL14 (down-regulated 6%, Q-value=0.0257), compared with controls. Among statin users, diabetes cases had marginal but insignificantly different expression of ZNF532 (up-regulated 15%, Q-value=0.0584), CXORF21 (up-regulated 11%, Q-value=0.0584), and ZNHIT3 (up-regulated 19%, Q-value=0.0959), compared with controls. These genes comprise potential targets for future expression or mechanistic research on medication-related diabetes development.


Related Articles

  • Statins and risk of developing diabetes. Kuritzky, Louis // Clinical Cardiology Alert;May2010 Primary Care, p9 

    The article discusses a collaborative meta-analysis performed by Professor Naveed Sattar and colleagues on 13 randomized statin trials to establish a link between statin therapy and the risk of developing diabetes.

  • Statins: Potential diabetogenic agents? Evans, Marc // Diabetes Digest;2013, Vol. 12 Issue 3, p150 

    The article discusses the increase risk of diabetes associated with statin treatment which include simvastatin, rosuvastatin and atorvastatin. It highlights the benefits of hydroxymethyl glutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) for people with cardiovascular disease. It...

  • Impact of Statins on Gene Expression in Human Lung Tissues. Lane, Jérôme; van Eeden, Stephan F.; Obeidat, Ma’en; Sin, Don D.; Tebbutt, Scott J.; Timens, Wim; Postma, Dirkje S.; Laviolette, Michel; Paré, Peter D.; Bossé, Yohan // PLoS ONE;11/4/2015, Vol. 10 Issue 10, p1 

    Statins are 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors that alter the synthesis of cholesterol. Some studies have shown a significant association of statins with improved respiratory health outcomes of patients with asthma, chronic obstructive pulmonary disease and lung cancer....

  • High-dose statin therapy significantly affects T2D glycaemic control.  // Diabetes Digest;2012, Vol. 11 Issue 3, p140 

    The article presents a brief summary of the CORALL study by S. Simsek and colleagues, which compares the lipid-lowering effects of two statins, including rosuvastatin and atorvastatin in people with dislipidaemia and type 2 diabetes.

  • Statin benefits outweigh risk of developing diabetes.  // Pulse;2/24/2010, Vol. 70 Issue 6, p11 

    The article explores the benefits of statins that outweigh the risk of developing type 2 diabetes.

  • 398 Effect of statins on the course of CHF in patients with type 2 diabetes mellitus.  // European Journal of Heart Failure. Supplements;Jun2005, Vol. 4 Issue 1, p88 

    An abstract of the article "Effect of Statins on the Course of CHF in Patients With Type 2 Diabetes Mellitus," by G. Arutyunov and A. Beituganov is presented.

  • Clinical briefs.  // New Zealand Doctor;3/10/2010, p24 

    This section offers clinical news briefs including the role of statins in raising the relative risk of developing type 2 diabetes by nine percent, the risk posed by paroxetine to women taking tamoxifen for breast cancer, and the role of aspirin in helping women with breast cancer survive.

  • Experts debate statin acceleration of type 2 diabetes development.  // Endocrine Today;Mar2014, Vol. 12 Issue 3, p20 

    The article presents a discussion among medical experts on the issue of statin therapy and acceleration of type 2 diabetes.

  • Role of simvastatin as an immunomodulator in type 2 diabetes: response to Lopes-Virella et al. Petrou, Michelle; Gregoriades, Marialena; Vassiliou, Vassilios // Diabetes Care;Aug2004, Vol. 27 Issue 8, p2093 

    Presents a letter to the editor about the role of simvastatin as an immunomodulator in patients with type 2 diabetes.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics